Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Manjulatha Badam

Undersea and Hyperbaric Medicine San Antonio, TX Medical Doctor

NPI 1417013368 CMS profile 489078

8666 Huebner Rd, Ste 220, Vayu Advance Wound Clinic And Hyper, San Antonio, TX 78240

Open in the dashboard

General payments

$1,192

47 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Manjulatha Badam of San Antonio, TX is reported in the CMS Open Payments database as having received $1,192 across 47 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 66th percentile of Undersea and Hyperbaric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $226 2
2024 General $157 6
2023 General $151 6
2022 General $301 11
2021 General $179 12
2020 General $50 2
2019 General $129 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Manjulatha Badam
  • Undersea and Hyperbaric Medicine median
  • Middle half of Undersea and Hyperbaric Medicine
  • National median

In program year 2025, general payments to Manjulatha Badam were reported at $226. Among 121 Undersea and Hyperbaric Medicine profiles paid that year, the median was $208 and the middle half received between $52 and $518.

Show as a table
Year Manjulatha Badam Undersea and Hyperbaric Medicine median Middle half National median
2019 $129 $201 $85–$538 $163
2020 $50 $84 $31–$222 $114
2021 $179 $138 $52–$383 $132
2022 $301 $135 $51–$385 $149
2023 $151 $143 $75–$442 $160
2024 $157 $178 $80–$442 $164
2025 $226 $208 $52–$518 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Organogenesis Inc. $600 23 payments
  2. Smith+Nephew, Inc. $170 12 payments
  3. Revance Therapeutics, Inc. $139 1 payment
  4. Blueprint Medicines Corporation $87 1 payment
  5. Misonix Inc $64 2 payments
  6. Tactile Systems Technology Inc $42 3 payments
  7. Medline Industries, Inc. $30 1 payment
  8. ConvaTec Inc. $29 2 payments
  9. Osiris Therapeutics Inc. $18 1 payment
  10. Hydrofera LLC $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,192 47 payments
Products named General payments · program years 2019–2025
  1. Puraply $473 17 payments
  2. DAXI $139 1 payment
  3. GRAFIX PL $114 8 payments
  4. TheraSkin $64 2 payments
  5. COLLAGENASE SANTYL $32 3 payments
  6. FLEXITOUCH $29 2 payments
  7. ACTITOUCH $29 2 payments
  8. ENTRE $29 2 payments
  9. RENASYS GO v2 HOME $23 1 payment
  10. Puraply Antimicrobial $22 1 payment
  11. Other $142 11 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

30

Prescriptions dispensed, refills included

Drug cost

$163

Paid at the pharmacy, in all

Branded share of claims

46.7%

Brand-name drugs, not generics

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 14 $108
Levofloxacin Generic 16 $55

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero.

Billing to Medicare

Part B · data year 2024 · 30 billing codes

Paid by Medicare

$5,219,094

Of which drugs: $2,559,374

Medicare patients

156

Average age 75

Services billed

9,889

82 women, 74 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 60%
Arthritis 55%
Chronic kidney disease 51%
Ischemic heart disease 43%
Atrial fibrillation 33%
Heart failure 30%
Depression 26%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Complete ft, per square centimeter Q4271 Office 30 1,047 $1,368,077
Restorigin, per square centimeter Q4191 Office 30 728 $871,364
Novachor, per square centimeter Q4194 Office 13 160 $128,745
Puraply xt, per square centimeter Q4197 Office 13 674 $62,745

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

47 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Undersea and Hyperbaric Medicine in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record